$11.03
+0.310 (+2.89%)
At Close: Jul 13, 2026
Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates
12:15pm, Thursday, 12'th May 2022 Zacks Investment Research
Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Wednesday, 11'th May 2022 Zacks Investment Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Phreesia: Their Time Has Passed
10:38am, Tuesday, 10'th May 2022
Phreesia was a pioneer in reducing patient visitation paperwork in the clinical practice setting with their Phreesia Pad. They targeted small clinics,
CareCloud, Inc. (MTBC) Reports Q1 Loss, Tops Revenue Estimates
12:55pm, Monday, 09'th May 2022 Zacks Investment Research
CareCloud, Inc. (MTBC) delivered earnings and revenue surprises of 29.63% and 5.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
02:03pm, Thursday, 14'th Apr 2022 Benzinga
Upgrades
For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago qua
BIGZ: A Buy If You Can Stomach It
05:16am, Saturday, 09'th Apr 2022
BIGZ: A Buy If You Can Stomach It
IPO Preview: Mitesco Is Filling The Void In Primary Care
02:53pm, Friday, 01'st Apr 2022
IPO Preview: Mitesco Is Filling The Void In Primary Care
Expert Ratings For Phreesia
03:41pm, Thursday, 31'st Mar 2022 Benzinga
Phreesia (NYSE:PHR) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
3
0
0
Last 30D
2
1
2
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
09:15pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia, Inc. (PHR) CEO Chaim Indig on Q4 2022 Results - Earnings Call Transcript
08:39pm, Wednesday, 30'th Mar 2022
Phreesia, Inc. (PHR) CEO Chaim Indig on Q4 2022 Results - Earnings Call Transcript
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 30'th Mar 2022
Phreesia (PHR) delivered earnings and revenue surprises of 14.29% and 3.93%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Motus GI Holdings, Inc. (MOTS) Reports Q4 Loss, Misses Revenue Estimates
10:35pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 0% and 27.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?
07:52am, Thursday, 17'th Mar 2022 Zacks Investment Research
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Phreesia (PHR) Soars 5.9%: Is Further Upside Left in the Stock?
05:16am, Thursday, 17'th Mar 2022
Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
11:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sign In
Buy PHR